Using nanotechnology to target therapy for triple negative breast cancer
Official title: Nanotechnology for targeted therapy and fundamental understanding oftherapeutic resistance in triple negative breast cancer
Funded at Univ of Maryland, College Park · NIH-10814962 · Data updated 2026-11-12
This study is exploring new ways to treat triple negative breast cancer using tiny particles to deliver special molecules that can help stop cancer cells from growing, aiming to create better treatment options that work specifically for this type of cancer and have fewer side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of Maryland, College Park NIH-funded |
| Lab location | 1 site (College Park, United States) |
| Project start | April 1, 2020 |
| Project end | March 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $235,233 |
| NIH project number | 5R01CA243023-05 |
| Project ID | NIH-10814962 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with triple negative breast cancer, particularly those whose tumors exhibit TP53 and POLR2A genetic alterations.
✕Less likely to help
Patients with other types of breast cancer or those whose tumors do not have the specific genetic alterations targeted by this research may not benefit.
What this research studies
This research focuses on developing innovative therapies for triple negative breast cancer (TNBC), a type of breast cancer that currently lacks effective targeted treatments. The approach involves using nanotechnology to deliver small interfering RNA (siRNA) that can selectively inhibit cancer cell growth by targeting specific genetic alterations associated with TNBC. By understanding the genetic vulnerabilities of TNBC cells, particularly those with deletions in the TP53 and POLR2A genes, the research aims to create more effective treatment options. Patients may benefit from this targeted therapy that could improve treatment outcomes and reduce side effects compared to traditional therapies.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted treatment options for patients with triple negative breast cancer.
How similar studies have gone: Previous research has shown promise in using targeted therapies for cancer treatment, but this specific approach utilizing nanotechnology for TNBC is relatively novel.
Where this research is happening
-
Univ of Maryland, College Park
College Park, United States Active
Researchers
- Principal investigator: He, Xiaoming — Univ of Maryland, College Park
- Study coordinator: He, Xiaoming
Related research
Other NIH-funded projects on the same topics.
-
PET scans to track glutamine use in triple-negative breast cancer
This project uses special PET scans with an amino-acid tracer to see how triple-negative breast cancers use glutamine so doctors can better match metabolism-targeted treatments to patients.
-
Improving Targeted Therapy for Triple Negative Breast Cancer
This project aims to develop a new way to deliver targeted medicines directly to triple-negative breast cancer tumors using special RNA molecules.
-
Using PET imaging to understand glutamine metabolism in triple-negative breast cancer
This study is looking at how a substance called glutamine affects triple-negative breast cancer to find better ways to treat it, using special imaging to see how much glutamine is in the cancer cells and helping doctors choose the best therapies for patients.
-
Targeted therapy for triple-negative breast cancer using antibody-drug conjugates
This study is working on new treatments for triple-negative breast cancer that aim to target cancer cells directly while being kinder to healthy cells, so patients can have better outcomes with fewer side effects.
-
New treatment approach for triple negative breast cancer using targeted siRNA delivery
This study is testing a new way to deliver a special treatment directly to tumors in patients with triple negative breast cancer, making it easier for the medicine to reach the cancer and potentially improve how well it works.
-
Targeted therapy for aggressive breast cancer
This study is testing a new treatment for triple-negative breast cancer that uses tiny particles to deliver medicine directly to cancer cells, helping to stop them from spreading and improving how well the treatment works.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.